Beaumont, France

Yves Sagot

USPTO Granted Patents = 1 



Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yves Sagot: Innovator in Neurological Inflammatory Diseases

Introduction

Yves Sagot is a notable inventor based in Beaumont, France. He has made significant contributions to the field of medical research, particularly in the treatment and prevention of neurological inflammatory diseases. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Yves Sagot holds a patent for the "Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases." This invention relates to the use of an IL-18BP isoform that does not bind to IL-18, or an agonist thereof, for the treatment or prevention of neurological and/or inflammatory diseases. The preferred isoforms for use in this invention include IL-18BPb and IL-18BPd. This patent highlights his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Yves Sagot is currently associated with Merck Serono S.A., a leading biopharmaceutical company. His role at Merck Serono has allowed him to collaborate with other experts in the field and contribute to groundbreaking research. His work is characterized by a focus on innovative solutions to complex medical challenges.

Collaborations

Yves has worked alongside talented colleagues such as Yolande Chvatchko and Anne Corbaz. Their collaborative efforts have further enhanced the research and development of treatments for neurological inflammatory diseases.

Conclusion

Yves Sagot's contributions to the field of medical research, particularly through his patent on IL-18BP isoforms, demonstrate his dedication to improving healthcare. His work continues to inspire advancements in the treatment of neurological inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…